000			02236 a2200721 4500
005			20250517041604.0
264		0	_c20170309
008			201703s 0 0 eng d
022			_a1473-1150
024	7		_a10.1038/tpj.2015.49 _2doi
040			_aNLM _beng _cNLM
100	1		_aFabris, M
245	0	0	_aThe -308 TNFα and the -174 IL-6 promoter polymorphisms associate with effective anti-TNFα treatment in seronegative spondyloarthritis. _h[electronic resource]
260			_bThe pharmacogenomics journal _c06 2016
300			_a238-42 p. _bdigital
500			_aPublication Type: Journal Article; Multicenter Study
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aAntirheumatic Agents _xadverse effects
650	0	4	_aBiological Products _xadverse effects
650	0	4	_aChi-Square Distribution
650	0	4	_aDrug Substitution
650	0	4	_aFemale
650	0	4	_aGenetic Association Studies
650	0	4	_aHomozygote
650	0	4	_aHumans
650	0	4	_aInterleukin-6 _xgenetics
650	0	4	_aItaly
650	0	4	_aLogistic Models
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aMultivariate Analysis
650	0	4	_aOdds Ratio
650	0	4	_aPharmacogenomic Testing
650	0	4	_aPharmacogenomic Variants _xgenetics
650	0	4	_aPhenotype
650	0	4	_aPolymorphism, Single Nucleotide
650	0	4	_aPredictive Value of Tests
650	0	4	_aPromoter Regions, Genetic
650	0	4	_aRetrospective Studies
650	0	4	_aRisk Assessment
650	0	4	_aRisk Factors
650	0	4	_aSex Factors
650	0	4	_aSpondylarthritis _xblood
650	0	4	_aTime Factors
650	0	4	_aTreatment Failure
650	0	4	_aTumor Necrosis Factor-alpha _xantagonists & inhibitors
650	0	4	_aYoung Adult
700	1		_aQuartuccio, L
700	1		_aFabro, C
700	1		_aSacco, S
700	1		_aLombardi, S
700	1		_aRamonda, R
700	1		_aBiasi, D
700	1		_aPunzi, D
700	1		_aAdami, S
700	1		_aOlivieri, I
700	1		_aCurcio, F
700	1		_aDe Vita, S
773	0		_tThe pharmacogenomics journal _gvol. 16 _gno. 3 _gp. 238-42
856	4	0	_uhttps://doi.org/10.1038/tpj.2015.49 _zAvailable from publisher's website
999			_c25050198 _d25050198